About Embla Medical

Sveinn Sölvason, President and CEO, comments:
"Sales in Q1 2025 amounted to USD 203 million and organic growth came in at 4% driven by a strong finish to the quarter.

Growth was strong in our Prosthetics & Neuro Orthotics segment supported by continued momentum and solid volume growth in EMEA and APAC regions, while the year started out softer in Americas following a strong end to 2024.

Our EBITDA margin for the quarter was 18%; up 1%-point from Q1 2024."

Embla will host a conference call on April 29, 2025 at 09:00 CET / 7:00 GMT / 3:00 EST. Please visit our Investor Relations section for further information.

We serve our investors, by communicating in an informative and honest way. We are ambitious about the way we interact. It is our policy to provide investors, analysts and other stakeholders with comprehensive and accurate information to improve the understanding of the current and expected development of Embla Medical.